Document is current
Any future updates will be listed below
-
Authors
Liang, Roger J.
Taylor, Samuel
Nahiyaan, Navid
Song, Junho
Murphy, Charles J.
Dantas, Ezequiel
Cheng, Shuyuan
Hsu, Ting-Wei
Ramsamooj, Shakti
Grover, Rahul
Hwang, Seo-Kyoung
Ngo, Bryan
Cantley, Lewis C.
Rhee, Kyu Y.
Goncalves, Marcus D. https://orcid.org/0000-0002-0784-9248
-
Funding
Funding for this research was provided by:
National Institutes of Health (R35 CA197588, K08 CA230318, P50 CA211024)
National Institute of Allergy and Infectious Diseases (R25 AI 140472)
Standing up to Cancer (AACR-DT22-17)
National Science Foundation
National Cancer Institute (F99CA234950)
- License Information
-
More Information
Article History
Received: 13 July 2020
Accepted: 8 February 2021
First Online: 24 March 2021
Competing interests
: L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals. M.D.G. reports personal fees from Novartis, Petra Pharmaceuticals, and Bayer. He receives research support from Pfizer. L.C.C. and M.D.G. are inventors on patents (pending) for Combination Therapy for PI3K-associated Disease or Disorder, The Identification of Therapeutic Interventions to Improve Response to PI3K Inhibitors for Cancer Treatment, and Anti-Fructose Therapy for Colorectal and Small Intestine Cancers. L.C.C. and M.D.G. are co-founders and shareholders in Faeth Therapeutics. All other authors report no competing interests.
